US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immix Biopharma, Inc.

2.37

+0.18008.22%

Post-market: 2.410.0356+1.50%19:32 EDT

Volume:186.02K

Turnover:417.02K

Market Cap:66.07M

PE:-3.39

High:2.41

Open:2.20

Low:2.11

Close:2.19

Loading ...

Overview Company News Filings

Immix Biopharma Inc. Unveils Innovative Cell Therapy Platform for AL Amyloidosis and Other Serious Diseases

Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Immix Biopharma: Files for Offering of up to $13.5 Mln Shares of Common Stock - SEC Filing

THOMSON REUTERS

Immix Biopharma announces NXC-201 trial met primary endpoint

Immix Biopharma Inc. Announces At The Market Offering Agreement for Common Stock Sales

Immix Biopharma Announces Primary Endpoint Met in Positive Nxc-201 Interim Results Presented at Asco, Enabling Path to Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis

THOMSON REUTERS

BRIEF-Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Immix Biopharma expands U.S. clinical sites for NEXICART-2 trial

Immix Biopharma Inc: Anticipate Completing Nexicart-2 Clinical Trial Ahead of Schedule

THOMSON REUTERS

Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory Al Amyloidosis Trial Nexicart-2

THOMSON REUTERS

Immix Biopharma Announces Positive Results for Nxc-201 at Asco Oral Presentation, Enabling Pathway to Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis

THOMSON REUTERS

Immix Biopharma Inc. Files Amendment to 10-K Annual Report

Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview

Immix Biopharma Inc. Unveils Presentation on Pioneering Cell Therapy for AL Amyloidosis and Other Serious Diseases

Immix Biopharma’s Nxc-201 Nexicart-2 Clinical Trial Data Selected for Oral Presentation at Asco 2025

THOMSON REUTERS

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview

Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy

MT Newswires Live

BRIEF-Immix Biopharma Receives FDA RMAT Designation For NXC-201

Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IMMX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMX\",,,,,undefined,":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":2.37,"timestamp":1749240000000,"preClose":2.19,"halted":0,"volume":186024,"hourTrading":{"tag":"盘后","latestPrice":2.4056,"preClose":2.37,"latestTime":"19:32 EDT","volume":1173,"amount":2742.153,"timestamp":1749252752389},"delay":0,"floatShares":18071920,"shares":27877293,"eps":-0.700031,"marketStatus":"Market Closed","change":0.18,"latestTime":"06-06 16:00:00 EDT","open":2.2,"high":2.405,"low":2.11,"amount":417019.302,"amplitude":0.134703,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.700031,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":2.19,"preHourTrading":{"tag":"盘前","latestPrice":2.15,"preClose":2.19,"latestTime":"09:29 EDT","volume":3422,"amount":7491.649431,"timestamp":1749216599999},"postHourTrading":{"tag":"盘后","latestPrice":2.4056,"preClose":2.37,"latestTime":"19:32 EDT","volume":1173,"amount":2742.153,"timestamp":1749252752389},"volumeRatio":0.2917324287691188,"impliedVol":1.7939,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMX\",,,,,undefined,":{"symbol":"IMMX","floatShares":18071920,"roa":"-50.17%","roe":"-112.34%","lyrEps":-0.764111,"volumeRatio":0.2917324287691188,"shares":27877293,"dividePrice":0,"high":2.405,"amplitude":0.134703,"preClose":2.19,"low":2.11,"week52Low":1.26,"pbRate":"6.89","week52High":3,"institutionHeld":0,"latestPrice":2.37,"eps":-0.700031,"divideRate":0,"volume":186024,"delay":0,"ttmEps":-0.700031,"open":2.2,"prevYearClose":2.2,"prevWeekClose":2.34,"prevMonthClose":2.34,"prevQuarterClose":1.68,"fiveDayClose":2.34,"twentyDayClose":2.145,"sixtyDayClose":1.63},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMMX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541941670","title":"Immix Biopharma Inc. Unveils Innovative Cell Therapy Platform for AL Amyloidosis and Other Serious Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2541941670","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541941670?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:06","pubTimestamp":1749074782,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL8CZcD3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2540417068","title":"Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2540417068","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540417068?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:28","pubTimestamp":1749036480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 04, 2025 07:28 ET (11:28 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2540701160","title":"Immix Biopharma: Files for Offering of up to $13.5 Mln Shares of Common Stock -  SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2540701160","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540701160?lang=en_us&edition=fundamental","pubTime":"2025-06-04 03:10","pubTimestamp":1748977835,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2540701454","title":"Immix Biopharma announces NXC-201 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2540701454","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540701454?lang=en_us&edition=fundamental","pubTime":"2025-06-04 03:10","pubTimestamp":1748977819,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced meeting its primary endpoint of complete response rate for cell therapy NXC-201 at an oral presentation of interim...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-nxc-201-trial-met-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-nxc-201-trial-met-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NXC","BK4139","IMMX"],"gpt_icon":0},{"id":"2540701969","title":"Immix Biopharma Inc. Announces At The Market Offering Agreement for Common Stock Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2540701969","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540701969?lang=en_us&edition=fundamental","pubTime":"2025-06-04 03:01","pubTimestamp":1748977277,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. has entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC, allowing the company to offer and sell shares of its common stock at its discretion through the agent. The sales will be conducted under the company's effective Registration Statement on Form S-3. The agent will earn a commission of 3% on the gross sales proceeds and will also be reimbursed for certain specified expenses up to $50,000. The agreement enables Immix Biopharma to strategically sell shares in alignment with market conditions and company requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gather","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL4ngqwL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immix Biopharma Inc. Announces At The Market Offering Agreement for Common Stock Sales","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2540701618","title":"Immix Biopharma Announces Primary Endpoint Met in Positive Nxc-201 Interim Results Presented at Asco, Enabling Path to Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2540701618","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540701618?lang=en_us&edition=fundamental","pubTime":"2025-06-04 02:55","pubTimestamp":1748976900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA9NRT1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2537213178","title":"BRIEF-Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2537213178","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537213178?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:13","pubTimestamp":1748006003,"startTime":"0","endTime":"0","summary":"BRIEF-Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2May 23 (Reuters) - Immix Biopharma Inc IMMX.O:IMMIX BIOPHARMA FURTHER EXPANDS U.S. CLIN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nFWN3RV02J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2537134691","title":"Immix Biopharma expands U.S. clinical sites for NEXICART-2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2537134691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537134691?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:10","pubTimestamp":1748005819,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2. This milestone adds 10 sites since ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-expands-u-s-clinical-sites-for-nexicart-2-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-expands-u-s-clinical-sites-for-nexicart-2-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2537485131","title":"Immix Biopharma Inc: Anticipate Completing Nexicart-2 Clinical Trial Ahead of Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2537485131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537485131?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:05","pubTimestamp":1748005508,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nFWN3RV02J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2537131940","title":"Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory Al Amyloidosis Trial Nexicart-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2537131940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537131940?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:05","pubTimestamp":1748005500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nTUARQHPR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2537432924","title":"Immix Biopharma Announces Positive Results for Nxc-201 at Asco Oral Presentation, Enabling Pathway to Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2537432924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537432924?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:02","pubTimestamp":1747944120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA3YRMV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2536560658","title":"Immix Biopharma Inc. Files Amendment to 10-K Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2536560658","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536560658?lang=en_us&edition=fundamental","pubTime":"2025-05-20 05:20","pubTimestamp":1747689607,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. filed an amendment to the 10-K annual report for the fiscal year ended December 31, 2024. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDLc3Z1vY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2533562064","title":"Immix Biopharma Inc  expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533562064","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533562064?lang=en_us&edition=fundamental","pubTime":"2025-05-06 06:48","pubTimestamp":1746485285,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc  expected to post a loss of23cents a share - Earnings Preview Immix Biopharma Inc IMMX.OQ IMMX.O is expected to report resultson May 7 (estimated) for the period ending March 31 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD35P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2532235873","title":"Immix Biopharma Inc. Unveils Presentation on Pioneering Cell Therapy for AL Amyloidosis and Other Serious Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2532235873","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532235873?lang=en_us&edition=fundamental","pubTime":"2025-05-03 02:27","pubTimestamp":1746210421,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. has unveiled its latest presentation focusing on pioneering cell therapy for AL Amyloidosis and other serious diseases, with a dedicated team working on the development of NXC-201. This sterically-optimized CAR-T construct, developed through the N-GENIUS platform, features a \"digital filter\" that reduces non-specific activation, resulting in improved tolerability. The presentation highlights Immix's significant milestones, including FDA Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation for NXC-201, and reports on various data from clinical trials. The company plans to submit for FDA approval of NXC-201 in the coming years, with interim and final readouts scheduled. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nNDL19SHsN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2529682665","title":"Immix Biopharma’s Nxc-201 Nexicart-2 Clinical Trial Data Selected for Oral Presentation at Asco 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529682665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529682665?lang=en_us&edition=fundamental","pubTime":"2025-04-23 22:04","pubTimestamp":1745417040,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA1C5C4Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2529680520","title":"Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529680520","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529680520?lang=en_us&edition=fundamental","pubTime":"2025-04-23 22:04","pubTimestamp":1745417040,"startTime":"0","endTime":"0","summary":"— Oral presentation Tuesday, June 3, 2025 in Chicago —。“Safety and efficacy data from NEXICART-2, the first US trial of CAR-T in R/R light chain  amyloidosis, NXC-201”。Session Name: 652. Oral Abstract Session – Hematologic Malignancies—Plasma Cell Dyscrasia. About AL AmyloidosisAL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that build-up in the heart, kidney, liver, and other organs. This build-up causes progressive and widespread organ damage, including heart and renal failure, leading to high mortality rates.The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immix-biopharma-nxc-201-nexicart-140400135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AL","BK4183","BK4139","NXC","IMMX","IE0034390439.USD","CAR","BK4104","IE00B19Z6F94.USD","BK4572","BK4022","ODD","BK4230"],"gpt_icon":0},{"id":"2522880318","title":"Immix Biopharma Inc  expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522880318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522880318?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:15","pubTimestamp":1742933707,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc  expected to post a loss of23cents a share - Earnings Preview Immix Biopharma Inc IMMX.OQ IMMX.O is expected to report resultson May 7 (estimated) for the period ending March 31 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL5N3Q81XS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2510869097","title":"Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2510869097","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510869097?lang=en_us&edition=fundamental","pubTime":"2025-02-10 23:36","pubTimestamp":1739201762,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) said Monday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation to NXC-201 as a potential treatment for relapsed/refractory A","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK6522","IE00B19Z4B17.USD","IE00B66KJ199.SGD","IMMX","NXC","IE00B7SZL793.SGD","BK4157","BLZ.SI","AEIS","BK4139","BK6088","IE0031619046.USD"],"gpt_icon":0},{"id":"2510866728","title":"BRIEF-Immix Biopharma Receives FDA RMAT Designation For NXC-201","url":"https://stock-news.laohu8.com/highlight/detail?id=2510866728","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510866728?lang=en_us&edition=fundamental","pubTime":"2025-02-10 23:15","pubTimestamp":1739200519,"startTime":"0","endTime":"0","summary":"BRIEF-Immix Biopharma Receives FDA RMAT Designation For NXC-201Feb 10 (Reuters) - Immix Biopharma Inc IMMX.O:IMMIX BIOPHARMA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3P10W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2510865617","title":"Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2510865617","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510865617?lang=en_us&edition=fundamental","pubTime":"2025-02-10 22:40","pubTimestamp":1739198437,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced that the U.S. FDA has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of relapsed...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-receives-fda-rmat-designation-for-ncx-201-in-r-r-al-amyloidosis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-receives-fda-rmat-designation-for-ncx-201-in-r-r-al-amyloidosis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4104","IE0034390439.USD","AL","BK4022","IE00B19Z6F94.USD","IMMX","BK4139","CAR","BK4230","BK4572"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMMX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"IMMX","fiscalQuarterEnding":"2025/03","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-03-24","symbol":"IMMX","fiscalQuarterEnding":"2024/12","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.16},{"market":"US","date":"2024-11-12","symbol":"IMMX","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2024-08-12","symbol":"IMMX","fiscalQuarterEnding":"2024/06","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723435200000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2024-05-09","symbol":"IMMX","fiscalQuarterEnding":"2024/03","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMMX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1719892800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IMMX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IMMX","date":"2025-06-06","current":-2.921545,"percent":0.447462,"low":-37.240428,"twenty":-5.340508,"median":-2.75157,"eighty":-1.203382,"high":-0.384227,"avg":-4.38092,"sd":5.619284,"marketCap":61051271},"quantilePoints":[{"date":"2021-12-17","current":-22.068402,"twenty":-20.976016,"median":-17.642249,"eighty":-15.03674,"marketCap":52834756},{"date":"2021-12-23","current":-16.275446,"twenty":-19.828459,"median":-17.958163,"eighty":-15.532222,"marketCap":38965632},{"date":"2021-12-31","current":-19.640878,"twenty":-19.806391,"median":-18.096089,"eighty":-16.937498,"marketCap":47022932},{"date":"2022-01-07","current":-29.461317,"twenty":-29.957856,"median":-19.420194,"eighty":-17.952645,"marketCap":70534399},{"date":"2022-01-14","current":-32.219867,"twenty":-32.197799,"median":-20.247759,"eighty":-17.985748,"marketCap":77138743},{"date":"2022-01-21","current":-24.882123,"twenty":-32.142628,"median":-24.882123,"eighty":-18.007816,"marketCap":59571187},{"date":"2022-01-28","current":-21.461521,"twenty":-32.021251,"median":-22.399428,"eighty":-18.140226,"marketCap":51381800},{"date":"2022-02-04","current":-24.109729,"twenty":-31.756431,"median":-22.399428,"eighty":-18.493321,"marketCap":57721970},{"date":"2022-02-11","current":-23.282164,"twenty":-31.039208,"median":-23.30975,"eighty":-19.276749,"marketCap":55740667},{"date":"2022-02-18","current":-19.75122,"twenty":-30.222677,"median":-22.399428,"eighty":-19.59674,"marketCap":47287106},{"date":"2022-02-25","current":-17.654721,"twenty":-29.957856,"median":-22.123573,"eighty":-18.096089,"marketCap":42267804},{"date":"2022-03-04","current":-11.641082,"twenty":-29.902685,"median":-21.875304,"eighty":-17.875406,"marketCap":27870333},{"date":"2022-03-11","current":-10.261807,"twenty":-29.461317,"median":-21.461521,"eighty":-16.440959,"marketCap":24568161},{"date":"2022-03-18","current":-13.296212,"twenty":-27.199305,"median":-20.771884,"eighty":-15.03674,"marketCap":31832940},{"date":"2022-03-25","current":-11.751424,"twenty":-26.592424,"median":-19.75122,"eighty":-13.241041,"marketCap":28134507},{"date":"2022-04-01","current":-1.409519,"twenty":-26.482082,"median":-19.392608,"eighty":-11.751424,"marketCap":34369548},{"date":"2022-04-08","current":-1.028722,"twenty":-25.433833,"median":-18.096089,"eighty":-11.254885,"marketCap":25084227},{"date":"2022-04-14","current":-1.023038,"twenty":-24.992465,"median":-17.985748,"eighty":-10.416286,"marketCap":24945640},{"date":"2022-04-22","current":-0.818431,"twenty":-24.264208,"median":-17.765064,"eighty":-1.459534,"marketCap":19956512},{"date":"2022-04-29","current":-0.785819,"twenty":-24.109729,"median":-17.047841,"eighty":-1.310625,"marketCap":19161305},{"date":"2022-05-06","current":-0.848456,"twenty":-23.491814,"median":-15.778907,"eighty":-1.093514,"marketCap":20688655},{"date":"2022-05-13","current":-0.733622,"twenty":-23.293198,"median":-15.03674,"eighty":-0.9878,"marketCap":18119930},{"date":"2022-05-20","current":-1.191784,"twenty":-22.840796,"median":-13.351383,"eighty":-0.962793,"marketCap":29436208},{"date":"2022-05-27","current":-1.506595,"twenty":-22.465633,"median":-12.854844,"eighty":-0.975297,"marketCap":37211810},{"date":"2022-06-03","current":-1.394163,"twenty":-22.30012,"median":-12.247963,"eighty":-0.98098,"marketCap":34434809},{"date":"2022-06-10","current":-1.366055,"twenty":-22.16771,"median":-11.696253,"eighty":-0.986663,"marketCap":33740559},{"date":"2022-06-17","current":-1.366055,"twenty":-22.09047,"median":-11.254885,"eighty":-1.009398,"marketCap":33740559},{"date":"2022-06-24","current":-1.197406,"twenty":-22.046334,"median":-10.482491,"eighty":-1.025312,"marketCap":29575058},{"date":"2022-07-01","current":-1.461622,"twenty":-21.902889,"median":-10.344563,"eighty":-1.033234,"marketCap":36101010},{"date":"2022-07-08","current":-1.506595,"twenty":-21.737376,"median":-5.965715,"eighty":-1.047976,"marketCap":37211810},{"date":"2022-07-15","current":-1.534704,"twenty":-21.682205,"median":-1.669623,"eighty":-1.083284,"marketCap":37906060},{"date":"2022-07-22","current":-1.377298,"twenty":-21.461521,"median":-1.540325,"eighty":-1.107154,"marketCap":34018259},{"date":"2022-07-29","current":-1.371676,"twenty":-21.428418,"median":-1.529082,"eighty":-1.149213,"marketCap":33879409},{"date":"2022-08-05","current":-1.414851,"twenty":-21.086358,"median":-1.509406,"eighty":-1.161365,"marketCap":34945778},{"date":"2022-08-12","current":-1.308074,"twenty":-20.181554,"median":-1.484109,"eighty":-1.191784,"marketCap":34079789},{"date":"2022-08-19","current":-1.073155,"twenty":-19.88363,"median":-1.475262,"eighty":-1.182306,"marketCap":27959337},{"date":"2022-08-26","current":-1.09985,"twenty":-19.729152,"median":-1.461622,"eighty":-1.149213,"marketCap":28654843},{"date":"2022-09-02","current":-1.035781,"twenty":-19.629844,"median":-1.425082,"eighty":-1.094994,"marketCap":26985628},{"date":"2022-09-09","current":-0.961034,"twenty":-19.585706,"median":-1.416649,"eighty":-1.051798,"marketCap":25038212},{"date":"2022-09-16","current":-0.977051,"twenty":-19.19951,"median":-1.413839,"eighty":-1.023038,"marketCap":25455515},{"date":"2022-09-23","current":-0.787514,"twenty":-18.316774,"median":-1.407462,"eighty":-0.983253,"marketCap":20517424},{"date":"2022-09-30","current":-0.726114,"twenty":-18.096089,"median":-1.388541,"eighty":-0.966203,"marketCap":18917760},{"date":"2022-10-07","current":-0.69408,"twenty":-17.985748,"median":-1.380109,"eighty":-0.928999,"marketCap":18083153},{"date":"2022-10-14","current":-0.646028,"twenty":-17.985748,"median":-1.371676,"eighty":-0.916325,"marketCap":16831242},{"date":"2022-10-21","current":-0.630011,"twenty":-17.930577,"median":-1.366055,"eighty":-0.871234,"marketCap":16413939},{"date":"2022-10-28","current":-0.573951,"twenty":-17.875406,"median":-1.366055,"eighty":-0.854252,"marketCap":14953376},{"date":"2022-11-04","current":-0.485856,"twenty":-17.654721,"median":-1.352001,"eighty":-0.819985,"marketCap":12658207},{"date":"2022-11-11","current":-0.448265,"twenty":-17.213353,"median":-1.343568,"eighty":-0.800862,"marketCap":12186169},{"date":"2022-11-18","current":-0.665994,"twenty":-17.047841,"median":-1.333979,"eighty":-0.785819,"marketCap":18105187},{"date":"2022-11-25","current":-0.686486,"twenty":-16.562335,"median":-1.321082,"eighty":-0.77203,"marketCap":18662269},{"date":"2022-12-02","current":-0.588739,"twenty":-16.308549,"median":-1.309839,"eighty":-0.750858,"marketCap":16004985},{"date":"2022-12-09","current":-0.712102,"twenty":-15.480984,"median":-1.267676,"eighty":-0.736159,"marketCap":19358623},{"date":"2022-12-16","current":-0.968253,"twenty":-15.085866,"median":-1.244005,"eighty":-0.741064,"marketCap":26322156},{"date":"2022-12-23","current":-1.111698,"twenty":-15.03674,"median":-1.214271,"eighty":-0.746567,"marketCap":30221735},{"date":"2022-12-30","current":-1.173175,"twenty":-14.853091,"median":-1.211283,"eighty":-0.747676,"marketCap":31892983},{"date":"2023-01-06","current":-1.19879,"twenty":-14.201016,"median":-1.209622,"eighty":-0.747791,"marketCap":32589336},{"date":"2023-01-13","current":-1.127067,"twenty":-13.362417,"median":-1.203028,"eighty":-0.749439,"marketCap":30639547},{"date":"2023-01-20","current":-1.101452,"twenty":-13.285178,"median":-1.197406,"eighty":-0.751884,"marketCap":29943194},{"date":"2023-01-27","current":-1.229528,"twenty":-13.163802,"median":-1.200909,"eighty":-0.753717,"marketCap":33424960},{"date":"2023-02-03","current":-1.608632,"twenty":-12.744502,"median":-1.208649,"eighty":-0.758575,"marketCap":43730990},{"date":"2023-02-10","current":-1.357604,"twenty":-12.2921,"median":-1.211283,"eighty":-0.764481,"marketCap":36906727},{"date":"2023-02-17","current":-1.173175,"twenty":-12.148655,"median":-1.210595,"eighty":-0.769597,"marketCap":31892983},{"date":"2023-02-24","current":-1.101452,"twenty":-11.751424,"median":-1.203913,"eighty":-0.774166,"marketCap":29943194},{"date":"2023-03-03","current":-1.075837,"twenty":-11.751424,"median":-1.198098,"eighty":-0.77443,"marketCap":29246840},{"date":"2023-03-10","current":-0.922146,"twenty":-11.641082,"median":-1.191784,"eighty":-0.785819,"marketCap":25068720},{"date":"2023-03-17","current":-0.932392,"twenty":-11.365227,"median":-1.185983,"eighty":-0.785819,"marketCap":25347261},{"date":"2023-03-24","current":-0.935614,"twenty":-11.254885,"median":-1.179936,"eighty":-0.787514,"marketCap":25434844},{"date":"2023-03-31","current":-3.073723,"twenty":-10.915583,"median":-1.185983,"eighty":-0.791513,"marketCap":25295856},{"date":"2023-04-06","current":-2.938614,"twenty":-10.569109,"median":-1.191784,"eighty":-0.796068,"marketCap":24183950},{"date":"2023-04-14","current":-2.98928,"twenty":-10.438354,"median":-1.197406,"eighty":-0.800131,"marketCap":24600914},{"date":"2023-04-21","current":-3.175054,"twenty":-10.383183,"median":-1.20347,"eighty":-0.807049,"marketCap":26129785},{"date":"2023-04-28","current":-3.884375,"twenty":-10.328012,"median":-1.210595,"eighty":-0.808596,"marketCap":31967290},{"date":"2023-05-05","current":-4.576322,"twenty":-10.272841,"median":-1.214215,"eighty":-0.816464,"marketCap":37661819},{"date":"2023-05-11","current":-3.813602,"twenty":-7.053908,"median":-1.216776,"eighty":-0.819363,"marketCap":31384849},{"date":"2023-05-19","current":-2.841134,"twenty":-4.874631,"median":-1.234651,"eighty":-0.836103,"marketCap":26642250},{"date":"2023-05-26","current":-2.380008,"twenty":-4.766155,"median":-1.244451,"eighty":-0.847813,"marketCap":22318115},{"date":"2023-06-02","current":-3.190234,"twenty":-4.657679,"median":-1.251483,"eighty":-0.848456,"marketCap":29915874},{"date":"2023-06-09","current":-3.254359,"twenty":-4.562763,"median":-1.270512,"eighty":-0.850774,"marketCap":30517199},{"date":"2023-06-16","current":-3.783393,"twenty":-4.400049,"median":-1.307224,"eighty":-0.856388,"marketCap":35478123},{"date":"2023-06-23","current":-4.10402,"twenty":-4.223113,"median":-1.309839,"eighty":-0.860781,"marketCap":38484743},{"date":"2023-06-30","current":-4.376552,"twenty":-4.23227,"median":-1.321082,"eighty":-0.865539,"marketCap":41040371},{"date":"2023-07-07","current":-4.152114,"twenty":-4.486677,"median":-1.332157,"eighty":-0.869324,"marketCap":38935736},{"date":"2023-07-14","current":-3.735299,"twenty":-4.39579,"median":-1.337947,"eighty":-0.871041,"marketCap":35027129},{"date":"2023-07-21","current":-3.572376,"twenty":-4.261126,"median":-1.345284,"eighty":-0.89609,"marketCap":33499345},{"date":"2023-07-28","current":-3.503009,"twenty":-4.195644,"median":-1.34919,"eighty":-0.905882,"marketCap":32848872},{"date":"2023-08-04","current":-3.503009,"twenty":-4.184638,"median":-1.356208,"eighty":-0.90747,"marketCap":32848872},{"date":"2023-08-11","current":-3.29491,"twenty":-4.158526,"median":-1.366055,"eighty":-0.911914,"marketCap":30897454},{"date":"2023-08-18","current":-2.330617,"twenty":-4.113639,"median":-1.367895,"eighty":-0.915656,"marketCap":26547513},{"date":"2023-08-25","current":-2.916846,"twenty":-4.034399,"median":-1.377298,"eighty":-0.920982,"marketCap":33225108},{"date":"2023-09-01","current":-2.902547,"twenty":-3.980385,"median":-1.38292,"eighty":-0.922146,"marketCap":33062240},{"date":"2023-09-08","current":-3.560267,"twenty":-3.968181,"median":-1.391352,"eighty":-0.923054,"marketCap":40554176},{"date":"2023-09-15","current":-3.631759,"twenty":-3.972707,"median":-1.409519,"eighty":-0.92366,"marketCap":41368517},{"date":"2023-09-22","current":-4.932901,"twenty":-4.034479,"median":-1.414345,"eighty":-0.926863,"marketCap":56189522},{"date":"2023-09-29","current":-6.358344,"twenty":-4.1851,"median":-1.416649,"eighty":-0.928999,"marketCap":72426414},{"date":"2023-10-06","current":-6.479291,"twenty":-4.315729,"median":-1.429506,"eighty":-0.931035,"marketCap":73804091},{"date":"2023-10-13","current":-5.615385,"twenty":-4.616006,"median":-1.461622,"eighty":-0.934325,"marketCap":63963545},{"date":"2023-10-20","current":-4.872427,"twenty":-4.777335,"median":-1.471175,"eighty":-0.943737,"marketCap":55500676},{"date":"2023-10-27","current":-6.375622,"twenty":-4.847512,"median":-1.475262,"eighty":-0.949152,"marketCap":72623225},{"date":"2023-11-03","current":-6.064616,"twenty":-4.932901,"median":-1.484109,"eighty":-0.950356,"marketCap":69080629},{"date":"2023-11-10","current":-6.410178,"twenty":-5.131598,"median":-1.509406,"eighty":-0.958007,"marketCap":73016847},{"date":"2023-11-17","current":-6.195423,"twenty":-5.719054,"median":-1.529082,"eighty":-0.961034,"marketCap":87580854},{"date":"2023-11-24","current":-6.703742,"twenty":-5.892712,"median":-1.540325,"eighty":-0.965169,"marketCap":94766658},{"date":"2023-12-01","current":-7.181577,"twenty":-6.076855,"median":-1.603509,"eighty":-0.967843,"marketCap":101521514},{"date":"2023-12-08","current":-7.01293,"twenty":-6.195898,"median":-1.669623,"eighty":-0.968253,"marketCap":99137447},{"date":"2023-12-15","current":-7.982654,"twenty":-6.218411,"median":-2.022607,"eighty":-0.97102,"marketCap":112845832},{"date":"2023-12-22","current":-10.034533,"twenty":-6.379078,"median":-2.409758,"eighty":-0.973043,"marketCap":141851979},{"date":"2023-12-29","current":-9.430212,"twenty":-6.451646,"median":-2.432071,"eighty":-0.974846,"marketCap":133309073},{"date":"2024-01-05","current":-8.50265,"twenty":-6.565681,"median":-2.473599,"eighty":-0.977051,"marketCap":120196705},{"date":"2024-01-12","current":-8.685352,"twenty":-6.703742,"median":-2.585988,"eighty":-0.97757,"marketCap":122779444},{"date":"2024-01-19","current":-7.518873,"twenty":-6.911741,"median":-2.60785,"eighty":-0.978313,"marketCap":106289648},{"date":"2024-01-26","current":-5.256184,"twenty":-7.018552,"median":-2.655395,"eighty":-0.982302,"marketCap":74303417},{"date":"2024-02-02","current":-5.466993,"twenty":-6.911741,"median":-2.795833,"eighty":-0.986834,"marketCap":77283501},{"date":"2024-02-09","current":-5.804128,"twenty":-6.774012,"median":-2.816758,"eighty":-0.987729,"marketCap":82049361},{"date":"2024-02-16","current":-5.229106,"twenty":-6.712174,"median":-2.843244,"eighty":-0.988695,"marketCap":73920631},{"date":"2024-02-23","current":-5.498647,"twenty":-6.703742,"median":-2.873951,"eighty":-0.994969,"marketCap":77730973},{"date":"2024-03-01","current":-6.019761,"twenty":-6.693474,"median":-2.904837,"eighty":-1.003911,"marketCap":85097634},{"date":"2024-03-08","current":-6.073669,"twenty":-6.663866,"median":-2.910842,"eighty":-1.008419,"marketCap":85859703},{"date":"2024-03-15","current":-5.10332,"twenty":-6.640353,"median":-2.938614,"eighty":-1.009238,"marketCap":72142472},{"date":"2024-03-22","current":-5.462708,"twenty":-6.634794,"median":-2.972392,"eighty":-1.015386,"marketCap":77222928},{"date":"2024-03-28","current":-5.516617,"twenty":-6.623022,"median":-3.014613,"eighty":-1.020906,"marketCap":77984996},{"date":"2024-04-05","current":-4.808357,"twenty":-6.594122,"median":-3.042817,"eighty":-1.023666,"marketCap":74173940},{"date":"2024-04-12","current":-4.945249,"twenty":-6.572627,"median":-3.073723,"eighty":-1.026253,"marketCap":76285653},{"date":"2024-04-19","current":-3.781661,"twenty":-6.536582,"median":-3.124388,"eighty":-1.031174,"marketCap":58336088},{"date":"2024-04-26","current":-3.593434,"twenty":-6.487476,"median":-3.158168,"eighty":-1.035224,"marketCap":55432482},{"date":"2024-05-03","current":-3.953922,"twenty":-6.475173,"median":-3.175054,"eighty":-1.037469,"marketCap":60993385},{"date":"2024-05-10","current":-3.731407,"twenty":-6.445469,"median":-3.190234,"eighty":-1.04472,"marketCap":57560857},{"date":"2024-05-17","current":-3.263275,"twenty":-6.403267,"median":-3.190234,"eighty":-1.053237,"marketCap":59409141},{"date":"2024-05-24","current":-3.07473,"twenty":-6.385989,"median":-3.190496,"eighty":-1.057425,"marketCap":55976613},{"date":"2024-05-31","current":-3.03122,"twenty":-6.372166,"median":-3.190496,"eighty":-1.060468,"marketCap":55184491},{"date":"2024-06-07","current":-2.988868,"twenty":-6.351433,"median":-3.175054,"eighty":-1.060468,"marketCap":54413458},{"date":"2024-06-14","current":-3.017886,"twenty":-6.323788,"median":-3.168385,"eighty":-1.060468,"marketCap":54941744},{"date":"2024-06-21","current":-2.785741,"twenty":-6.296199,"median":-3.161751,"eighty":-1.064566,"marketCap":50715456},{"date":"2024-06-28","current":-3.090431,"twenty":-6.282377,"median":-3.158171,"eighty":-1.065591,"marketCap":56262459},{"date":"2024-07-05","current":-3.554721,"twenty":-6.254675,"median":-3.158171,"eighty":-1.065591,"marketCap":64715035},{"date":"2024-07-12","current":-2.916322,"twenty":-6.209345,"median":-3.158168,"eighty":-1.070714,"marketCap":53092743},{"date":"2024-07-15","current":-3.061413,"twenty":-6.207036,"median":-3.158166,"eighty":-1.071202,"marketCap":55734173},{"date":"2024-08-02","current":-3.017886,"twenty":-6.204727,"median":-3.149722,"eighty":-1.07169,"marketCap":54941744},{"date":"2024-08-09","current":-2.901813,"twenty":-6.196849,"median":-3.133958,"eighty":-1.074228,"marketCap":52828600},{"date":"2024-08-16","current":-2.727429,"twenty":-6.184568,"median":-3.121919,"eighty":-1.075837,"marketCap":51881405},{"date":"2024-08-23","current":-3.189215,"twenty":-6.151983,"median":-3.124388,"eighty":-1.077452,"marketCap":60665558},{"date":"2024-08-30","current":-3.059338,"twenty":-6.126842,"median":-3.121919,"eighty":-1.082358,"marketCap":58195015},{"date":"2024-09-06","current":-3.030476,"twenty":-6.115383,"median":-3.11765,"eighty":-1.08762,"marketCap":57646005},{"date":"2024-09-13","current":-2.616311,"twenty":-6.073669,"median":-3.10494,"eighty":-1.093836,"marketCap":49767718},{"date":"2024-09-20","current":-2.554258,"twenty":-6.071858,"median":-3.096621,"eighty":-1.094187,"marketCap":48587347},{"date":"2024-09-27","current":-2.294503,"twenty":-6.055645,"median":-3.0882,"eighty":-1.094875,"marketCap":43646261},{"date":"2024-10-04","current":-1.933732,"twenty":-6.018828,"median":-3.074226,"eighty":-1.096448,"marketCap":36783641},{"date":"2024-10-11","current":-1.991456,"twenty":-6.007724,"median":-3.06426,"eighty":-1.097509,"marketCap":37881661},{"date":"2024-10-18","current":-2.438812,"twenty":-5.972157,"median":-3.060376,"eighty":-1.10017,"marketCap":46391309},{"date":"2024-10-25","current":-2.294503,"twenty":-5.941702,"median":-3.03122,"eighty":-1.101452,"marketCap":43646261},{"date":"2024-10-31","current":-2.381088,"twenty":-5.916977,"median":-3.023057,"eighty":-1.101452,"marketCap":45293290},{"date":"2024-11-08","current":-2.525397,"twenty":-5.911944,"median":-3.017886,"eighty":-1.101452,"marketCap":48038338},{"date":"2024-11-15","current":-2.035664,"twenty":-5.909113,"median":-3.016045,"eighty":-1.101452,"marketCap":44562371},{"date":"2024-11-22","current":-2.111059,"twenty":-5.888612,"median":-2.996328,"eighty":-1.106575,"marketCap":46212830},{"date":"2024-11-29","current":-2.65139,"twenty":-5.866126,"median":-2.988868,"eighty":-1.110673,"marketCap":58041114},{"date":"2024-12-06","current":-3.166589,"twenty":-5.85853,"median":-2.974359,"eighty":-1.111698,"marketCap":69319245},{"date":"2024-12-13","current":-2.676521,"twenty":-5.85743,"median":-2.967105,"eighty":-1.123993,"marketCap":58591266},{"date":"2024-12-20","current":-2.789614,"twenty":-5.829133,"median":-2.955503,"eighty":-1.127067,"marketCap":61066954},{"date":"2024-12-27","current":-2.638824,"twenty":-5.811316,"median":-2.943891,"eighty":-1.127067,"marketCap":57766037},{"date":"2025-01-03","current":-2.764482,"twenty":-5.804128,"median":-2.938614,"eighty":-1.127067,"marketCap":60516801},{"date":"2025-01-10","current":-2.827311,"twenty":-5.790569,"median":-2.938614,"eighty":-1.129098,"marketCap":61892183},{"date":"2025-01-17","current":-2.588561,"twenty":-5.735516,"median":-2.916584,"eighty":-1.137241,"marketCap":56665732},{"date":"2025-01-24","current":-2.575995,"twenty":-5.73225,"median":-2.915797,"eighty":-1.137313,"marketCap":56390655},{"date":"2025-01-31","current":-2.475468,"twenty":-5.73225,"median":-2.904837,"eighty":-1.137313,"marketCap":54190044},{"date":"2025-02-07","current":-2.538297,"twenty":-5.719054,"median":-2.903771,"eighty":-1.147559,"marketCap":55565426},{"date":"2025-02-14","current":-2.5006,"twenty":-5.615385,"median":-2.901813,"eighty":-1.148076,"marketCap":54740197},{"date":"2025-02-21","current":-2.236717,"twenty":-5.579497,"median":-2.888249,"eighty":-1.152623,"marketCap":48963593},{"date":"2025-02-28","current":-1.985401,"twenty":-5.541774,"median":-2.868902,"eighty":-1.165176,"marketCap":43462066},{"date":"2025-03-07","current":-2.073362,"twenty":-5.534586,"median":-2.845354,"eighty":-1.172146,"marketCap":45387601},{"date":"2025-03-14","current":-1.985401,"twenty":-5.520211,"median":-2.842004,"eighty":-1.173175,"marketCap":43462066},{"date":"2025-03-21","current":-2.286981,"twenty":-5.502241,"median":-2.829268,"eighty":-1.174313,"marketCap":50063899},{"date":"2025-03-28","current":-2.193309,"twenty":-5.498647,"median":-2.816758,"eighty":-1.178868,"marketCap":47404804},{"date":"2025-04-04","current":-2.026566,"twenty":-5.473324,"median":-2.814746,"eighty":-1.182724,"marketCap":43800930},{"date":"2025-04-11","current":-1.876497,"twenty":-5.463565,"median":-2.796559,"eighty":-1.183421,"marketCap":40557444},{"date":"2025-04-17","current":-2.01374,"twenty":-5.462708,"median":-2.786951,"eighty":-1.186495,"marketCap":43523709},{"date":"2025-04-25","current":-2.244614,"twenty":-5.451927,"median":-2.764482,"eighty":-1.190488,"marketCap":48513689},{"date":"2025-05-02","current":-2.616579,"twenty":-5.433958,"median":-2.746872,"eighty":-1.191784,"marketCap":56553100},{"date":"2025-05-09","current":-2.751256,"twenty":-5.40031,"median":-2.741859,"eighty":-1.192914,"marketCap":59463921},{"date":"2025-05-16","current":-2.77262,"twenty":-5.376785,"median":-2.741859,"eighty":-1.19591,"marketCap":57939205},{"date":"2025-05-23","current":-3.215034,"twenty":-5.372861,"median":-2.751256,"eighty":-1.198236,"marketCap":67184276},{"date":"2025-05-30","current":-3.001587,"twenty":-5.371163,"median":-2.741859,"eighty":-1.200485,"marketCap":62723909},{"date":"2025-06-06","current":-2.921545,"twenty":-5.340508,"median":-2.75157,"eighty":-1.203382,"marketCap":61051271}],"updateTime":1749393318550}}}